Image-guided high intensity focused ultrasound to treat breast cancerStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Magtrace/Sentimag MT599 (MIB263)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC